The US FDA has approved Hernexeos (zongertinib) from Boehringer Ingelheim for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. The Hernexeos FDA approval, announced on February 26, 2026, makes zongertinib the first oral, targeted therapy available as an initial treatment option for the patient subset.
The decision follows a prior accelerated approval in August 2025 for previously treated patients, extending the drug’s label. Boehringer Ingelheim developed zongertinib internally under the code BI 1810631. The agency also granted the drug a Commissioner’s National Priority Voucher and Breakthrough Therapy Designation for the first-line setting, reflecting the severity of the condition and the absence of prior mutation-specific options for treatment-naïve patients.
Accelerated approval conditions
The indication was approved under the FDA’s accelerated approval pathway, based on objective response rate (ORR) and duration of response (DoR). Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial. Boehringer Ingelheim is currently enrolling patients in Beamion LUNG-2 (NCT06151574), a Phase III randomized study evaluating zongertinib as a first-line HER2 mutant lung cancer therapy against standard treatment.
The approved indication covers adults with unresectable or metastatic non-squamous NSCLC with HER2+ tumors. Zongertinib is an irreversible tyrosine kinase inhibitor (TKI) that selectively targets HER2 while sparing EGFR signaling, a design feature intended to reduce the off-target toxicities that have limited earlier-generation HER-family kinase inhibitors.
The approval was supported by data from a cohort of 72 treatment-naïve patients enrolled in the Phase Ib Beamion LUNG-1 trial. In this cohort, zongertinib demonstrated an ORR of 76%, comprising complete responses in 11% of patients and partial responses in 65%. Among responders, 64% maintained their response for six months or longer. These results were assessed by blinded independent central review using RECIST v1.1 criteria.
Safety data were drawn from a pooled population of 292 patients with HER2-mutant NSCLC, encompassing both treatment-naïve and previously treated individuals. The most common adverse reactions occurring in more than 20% of patients were diarrhea (54%), rash (28%), hepatotoxicity (27%), fatigue (25%), nausea (23%), musculoskeletal pain (21%), and upper respiratory tract infection (20%). Adverse events led to permanent dose discontinuation in 6% of treatment-naïve patients. Serious but less frequent safety signals included interstitial lung disease or pneumonitis (4.1% of the pooled population, with one fatal case), cardiac toxicity manifesting as decreased left ventricular ejection fraction (1.7%), and hepatotoxicity requiring liver function monitoring throughout treatment.
What this means for HER2-mutant NSCLC treatment
HER2 mutations occur in approximately 2%-4% of NSCLC cases, a rare molecular subset that has historically lacked dedicated treatment options. The mutations are associated with a poor prognosis and a higher incidence of brain metastases compared with other NSCLC driver alterations. Although HER2 was identified as a lung cancer driver more than two decades ago, the translation of that knowledge into approved, mutation-specific therapies has been slow. Prior to the emergence of HER2 targeted therapy for lung cancer, patients with this molecular profile were typically managed with platinum-based chemotherapy combined with immunotherapy, regimens not designed around their specific oncogenic driver. Approximately half of these patients do not respond to such conventional approaches, according to patient advocacy groups cited in the company’s announcement.
The approval of Hernexeos for advanced NSCLC in the first-line setting addresses this gap directly. It allows clinicians to act on the identification of a HER2 activating mutation at the point of initial molecular profiling, rather than reserving targeted treatment for later lines. The oral, once-daily dosing regimen also distinguishes zongertinib from the only other FDA approved HER2 non-small cell lung cancer therapy, trastuzumab deruxtecan (Enhertu, Daiichi Sankyo/AstraZeneca), an intravenously administered antibody-drug conjugate that received accelerated approval in August 2022 for previously treated patients with HER2-mutant NSCLC. Trastuzumab deruxtecan demonstrated an ORR of approximately 58% in that setting but has not been approved for treatment-naïve patients.